Trials / Completed
CompletedNCT06388642
Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients
A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients With Erythropoietic Protoporphyria (EPP)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Clinuvel Europe Limited · Industry
- Sex
- All
- Age
- 12 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the concentration of afamelanotide in serum after the administration of afamelanotide in adolescent and adult EPP patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afamelanotide 16mg implant | afamelanotide 16mg implant will be administered to each patient during the study. |
Timeline
- Start date
- 2024-03-07
- Primary completion
- 2024-10-28
- Completion
- 2025-01-20
- First posted
- 2024-04-29
- Last updated
- 2026-03-25
Locations
2 sites across 2 countries: Belgium, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06388642. Inclusion in this directory is not an endorsement.